StreetInsider.com News Articles

Form 4 Theravance Biopharma, For: May 20 Filed by: Winningham Rick E

Fri, 22 May 2026 18:28:00 -0400

si-local-file:///var/storage/secattach/20260522/26543181.html

Form 4 Theravance Biopharma, For: May 20 Filed by: Winningham Rick E

Fri, 22 May 2026 18:28:00 -0400

si-local-file:///var/storage/secattach/20260522/26543181.html

Form 4 Theravance Biopharma, For: May 20 Filed by: Sawaf Aziz

Fri, 22 May 2026 18:25:00 -0400

si-local-file:///var/storage/secattach/20260522/26543174.html

Form 4 Theravance Biopharma, For: May 20 Filed by: Sawaf Aziz

Fri, 22 May 2026 18:25:00 -0400

si-local-file:///var/storage/secattach/20260522/26543174.html

Form 4 Theravance Biopharma, For: May 20 Filed by: Miller Aine

Fri, 22 May 2026 18:22:00 -0400

si-local-file:///var/storage/secattach/20260522/26543171.html

Form 4 Theravance Biopharma, For: May 20 Filed by: Miller Aine

Fri, 22 May 2026 18:22:00 -0400

si-local-file:///var/storage/secattach/20260522/26543171.html

Form 4 Theravance Biopharma, For: May 20 Filed by: Grimaud Brett A.

Fri, 22 May 2026 18:20:00 -0400

si-local-file:///var/storage/secattach/20260522/26543169.html

Form 4 Theravance Biopharma, For: May 20 Filed by: Grimaud Brett A.

Fri, 22 May 2026 18:20:00 -0400

si-local-file:///var/storage/secattach/20260522/26543169.html

Form 4 Theravance Biopharma, For: May 20 Filed by: Farnum Rhonda

Fri, 22 May 2026 18:18:00 -0400

si-local-file:///var/storage/secattach/20260522/26543164.html

Form 4 Theravance Biopharma, For: May 20 Filed by: Farnum Rhonda

Fri, 22 May 2026 18:18:00 -0400

si-local-file:///var/storage/secattach/20260522/26543164.html

Form 10-Q Theravance Biopharma, For: Mar 31

Thu, 07 May 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20260507/26449765.html

Form 10-Q Theravance Biopharma, For: Mar 31

Thu, 07 May 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20260507/26449765.html

Theravance Biopharma (TBPH) Misses Q1 EPS by 7c

Thu, 07 May 2026 08:36:14 -0400

Theravance Biopharma (NASDAQ: TBPH) reported Q1 EPS of ($0.10), $0.07 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $17.69 million versus the consensus estimate of $18 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.

Form 8-K Theravance Biopharma, For: May 07

Thu, 07 May 2026 08:36:00 -0400

si-local-file:///var/storage/secattach/20260507/26449294.html

Form 8-K Theravance Biopharma, For: May 07

Thu, 07 May 2026 08:36:00 -0400

si-local-file:///var/storage/secattach/20260507/26449294.html

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

Thu, 07 May 2026 08:30:00 -0400

YUPELRI^® Collaboration Revenue increased 15% year-over-year¹, from $15.4 million to $17.7 million, driven by continued Net Sales growth and improved operating leverage
All Hatch-Waxman litigation relating to YUPELRI^® has been resolved following settlement with Mankind Pharma in March
Organizational restructuring and cost reduction initiatives on track; delivered ~20% reduction in Operating Expenses year-over-year (excluding restructuring items)
Q1 2026 TRELEGY net sales, reported by GSK, of $873 million, up 2% year-over-year; high confidence in achieving the $100 million 2026 milestone payment²
Strategic Review Committee actively evaluating a range of opportunities to maximize shareholder value
Quarter-end cash balance of $395 million and no debt

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

Thu, 07 May 2026 08:30:00 -0400

YUPELRI^® Collaboration Revenue increased 15% year-over-year¹, from $15.4 million to $17.7 million, driven by continued Net Sales growth and improved operating leverage
All Hatch-Waxman litigation relating to YUPELRI^® has been resolved following settlement with Mankind Pharma in March
Organizational restructuring and cost reduction initiatives on track; delivered ~20% reduction in Operating Expenses year-over-year (excluding restructuring items)
Q1 2026 TRELEGY net sales, reported by GSK, of $873 million, up 2% year-over-year; high confidence in achieving the $100 million 2026 milestone payment²
Strategic Review Committee actively evaluating a range of opportunities to maximize shareholder value
Quarter-end cash balance of $395 million and no debt

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

Thu, 07 May 2026 08:30:00 -0400

YUPELRI^® Collaboration Revenue increased 15% year-over-year¹, from $15.4 million to $17.7 million, driven by continued Net Sales growth and improved operating leverage
All Hatch-Waxman litigation relating to YUPELRI^® has been resolved following settlement with Mankind Pharma in March
Organizational restructuring and cost reduction initiatives on track; delivered ~20% reduction in Operating Expenses year-over-year (excluding restructuring items)
Q1 2026 TRELEGY net sales, reported by GSK, of $873 million, up 2% year-over-year; high confidence in achieving the $100 million 2026 milestone payment²
Strategic Review Committee actively evaluating a range of opportunities to maximize shareholder value
Quarter-end cash balance of $395 million and no debt

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

Thu, 07 May 2026 08:30:00 -0400

YUPELRI^® Collaboration Revenue increased 15% year-over-year¹, from $15.4 million to $17.7 million, driven by continued Net Sales growth and improved operating leverage
All Hatch-Waxman litigation relating to YUPELRI^® has been resolved following settlement with Mankind Pharma in March
Organizational restructuring and cost reduction initiatives on track; delivered ~20% reduction in Operating Expenses year-over-year (excluding restructuring items)
Q1 2026 TRELEGY net sales, reported by GSK, of $873 million, up 2% year-over-year; high confidence in achieving the $100 million 2026 milestone payment²
Strategic Review Committee actively evaluating a range of opportunities to maximize shareholder value
Quarter-end cash balance of $395 million and no debt

Form DEF 14A Theravance Biopharma, For: Jun 12

Tue, 28 Apr 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260428/26385232.html

Form DEF 14A Theravance Biopharma, For: Jun 12

Tue, 28 Apr 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260428/26385232.html

Theravance Biopharma (TBPH) PT Raised to $17 at B.Riley

Tue, 07 Apr 2026 05:17:59 -0400

B.Riley analyst Mayank Mamtani raised the price target on Theravance Biopharma (NASDAQ: TBPH) to $17.00 (from $14.00) while maintaining a Neutral rating.

Form 4 Theravance Biopharma, For: Apr 01 Filed by: Winningham Rick E

Fri, 03 Apr 2026 18:10:00 -0400

si-local-file:///var/storage/secattach/20260403/26272795.html

Form 4 Theravance Biopharma, For: Apr 01 Filed by: Winningham Rick E

Fri, 03 Apr 2026 18:10:00 -0400

si-local-file:///var/storage/secattach/20260403/26272795.html

Form 4 Theravance Biopharma, For: Apr 01 Filed by: Sawaf Aziz

Fri, 03 Apr 2026 18:08:00 -0400

si-local-file:///var/storage/secattach/20260403/26272787.html